LLY · News · 20261106N

Distribution Channels - Hims & Hers

ELI LILLY & Co · 2026-11-06 · Importance 34 · Surprise 42 · In source text

Eli Lilly and Hims & Hers announced an agreement on November 6, 2026, to offer Zepbound (tirzepatide) and Foundayo (orforglipron) through the Hims & Hers platform. Eligible patients with prescriptions from licensed providers can access the medicines at Lilly’s self-pay prices without leaving the platform, with the medicines shipped to their homes. Self-pay prices start at $149 per month for Foundayo and $299 per month for Zepbound.

Key facts

• On November 6, 2026, Eli Lilly and Company and Hims & Hers Health announced an agreement to expand access to Zepbound (tirzepatide) and Foundayo (orforglipron). source
• Self-pay pricing through the Hims & Hers platform starts at $149 per month for Foundayo and $299 per month for Zepbound. source
• Under Eli Lilly's agreement with Hims & Hers, eligible patients prescribed treatment by a licensed provider on the Hims & Hers platform can access the same self-pay prices available to any patient without leaving that platform. source
• Through the Hims & Hers agreement, patients can receive an FDA-approved Eli Lilly medicine shipped directly to their home after a consultation and a prescription if their provider determines it is appropriate. source

Impact estimates